Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virus

Molecular Therapy

Volumn 21, Issue 3, 2013, Pages 561-569

  Uchida, Hiroaki ^a,h,i   Marzulli, Marco ^a   Nakano, Kenji ^a,h,i   Goins, William F ^a   Chan, Janet ^a   Hong, Chang Sook ^a   Mazzacurati, Lucia ^a,b   Yoo, Ji Young ^c   Haseley, Amy ^c,d   Nakashima, Hiroshi ^c   Baek, Hyunjung ^e   Kwon, Heechung ^e   Kumagai, Izumi ^f   Kuroki, Masahide ^g   Kaur, Balveen ^c   Chiocca, E Antonio ^c   Grandi, Paola ^a   Cohen, Justus B ^a   Glorioso, Joseph C ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e Korea Institute of Radiation and Medical Science   (South Korea)

^f TOHOKU UNIVERSITY   (Japan)

^g FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

ⁱ KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; ONCOLYTIC HERPES VIRUS; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN B; VIRUS GLYCOPROTEIN D; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER LOCALIZATION; CANCER SURVIVAL; CELL KILLING; CONTROLLED STUDY; FEMALE; GLIOBLASTOMA; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR RECOGNITION; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOLYTIC VIROTHERAPY; PROTEIN TARGETING; THERAPY EFFECT; TREATMENT RESPONSE; TUMOR VOLUME; TUMOR XENOGRAFT; VIRUS ENTRY; VIRUS INFECTIVITY; VIRUS RECOMBINANT;

ANIMALIA; MUS; SIMPLEXVIRUS;

EID: 84875215479     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2012.211     Document Type: Article

References (49)

1. Markert, JM, Gillespie, GY, Weichselbaum, RR, Roizman, B and Whitley, RJ (2000). Genetically engineered HSV in the treatment of glioma: a review. Rev Med Virol 10: 17-30.
2. Cattaneo, R, Miest, T, Shashkova, EV and Barry, MA (2008). Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Microbiol 6: 529-540.
3. Guo, ZS, Thorne, SH and Bartlett, DL (2008). Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses. Biochim Biophys Acta 1785: 217-231.
4. Friedman, GK, Cassady, KA, Beierle, EA, Markert, JM and Gillespie, GY (2012). Targeting pediatric cancer stem cells with oncolytic virotherapy. Pediatr Res 71(4 Pt 2): 500-510.
5. Manservigi, R, Argnani, R and Marconi, P (2010). HSV Recombinant Vectors for Gene Therapy. Open Virol J 4: 123-156.
6. Kambara, H, Okano, H, Chiocca, EA and Saeki, Y (2005). An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor. Cancer Res 65: 2832-2839.
7. Friedman, GK, Langford, CP, Coleman, JM, Cassady, KA, Parker, JN, Markert, JM et al. (2009). Engineered herpes simplex viruses efficiently infect and kill CD133+ human glioma xenograft cells that express CD111. J Neurooncol 95: 199-209.
8. Rueger, MA, Winkeler, A, Miletic, H, Kaestle, C, Richter, R, Schneider, G et al. (2005). Variability in infectivity of primary cell cultures of human brain tumors with HSV-1 amplicon vectors. Gene Ther 12: 588-596.
9. Friedman, GK, Pressey, JG, Reddy, AT, Markert, JM and Gillespie, GY (2009). Herpes simplex virus oncolytic therapy for pediatric malignancies. Mol Ther 17: 1125-1135.
10. Harrow, S, Papanastassiou, V, Harland, J, Mabbs, R, Petty, R, Fraser, M et al. (2004). HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival. Gene Ther 11: 1648-1658.
11. Markert, JM, Liechty, PG, Wang, W, Gaston, S, Braz, E, Karrasch, M et al. (2009). Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. Mol Ther 17: 199-207.
12. Markert, JM, Medlock, MD, Rabkin, SD, Gillespie, GY, Todo, T, Hunter, WD et al. (2000). Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 7: 867-874.
13. Connolly, SA, Jackson, JO, Jardetzky, TS and Longnecker, R (2011). Fusing structure and function: a structural view of the herpesvirus entry machinery. Nat Rev Microbiol 9: 369-381.
14. Montgomery, RI, Warner, MS, Lum, BJ and Spear, PG (1996). Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family. Cell 87: 427-436.
15. Geraghty, RJ, Krummenacher, C, Cohen, GH, Eisenberg, RJ and Spear, PG (1998). Entry of alphaherpesviruses mediated by poliovirus receptor-related protein 1 and poliovirus receptor. Science 280: 1618-1620.
16. Shukla, D, Liu, J, Blaiklock, P, Shworak, NW, Bai, X, Esko, JD et al. (1999). A novel role for 3-O-sulfated heparan sulfate in herpes simplex virus 1 entry. Cell 99: 13-22.
17. Zhou, G and Roizman, B (2006). Construction and properties of a herpes simplex virus 1 designed to enter cells solely via the IL-13alpha2 receptor. Proc Natl Acad Sci USA 103: 5508-5513.
18. Menotti, L, Cerretani, A, Hengel, H and Campadelli-Fiume, G (2008). Construction of a fully retargeted herpes simplex virus 1 recombinant capable of entering cells solely via human epidermal growth factor receptor 2. J Virol 82: 10153-10161.
19. Menotti, L, Nicoletti, G, Gatta, V, Croci, S, Landuzzi, L, De Giovanni, C et al. (2009). Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells. Proc Natl Acad Sci USA 106: 9039-9044.
20. Uchida, H, Chan, J, Goins, WF, Grandi, P, Kumagai, I, Cohen, JB et al. (2010). A double mutation in glycoprotein gB compensates for ineffective gD-dependent initiation of herpes simplex virus type 1 infection. J Virol 84: 12200-12209.
21. Yoon, M, Zago, A, Shukla, D and Spear, PG (2003). Mutations in the N termini of herpes simplex virus type 1 and 2 gDs alter functional interactions with the entry/fusion receptors HVEM, nectin-2, and 3-O-sulfated heparan sulfate but not with nectin-1. J Virol 77: 9221-9231.
22. Connolly, SA, Landsburg, DJ, Carfi, A, Whitbeck, JC, Zuo, Y, Wiley, DC et al. (2005). Potential nectin-1 binding site on herpes simplex virus glycoprotein d. J Virol 79: 1282-1295.
23. Tsvitov, M, Frampton, AR Jr, Shah, WA, Wendell, SK, Ozuer, A, Kapacee, Z et al. (2007). Characterization of soluble glycoprotein D-mediated herpes simplex virus type 1 infection. Virology 360: 477-491.
24. Cocchi, F, Menotti, L, Mirandola, P, Lopez, M and Campadelli-Fiume, G (1998). The ectodomain of a novel member of the immunoglobulin subfamily related to the poliovirus receptor has the attributes of a bona fide receptor for herpes simplex virus types 1 and 2 in human cells. J Virol 72: 9992-10002.
25. Schneider, U, Bullough, F, Vongpunsawad, S, Russell, SJ and Cattaneo, R (2000). Recombinant measles viruses efficiently entering cells through targeted receptors. J Virol 74: 9928-9936.
26. Tanaka, T, Huang, J, Hirai, S, Kuroki, M, Kuroki, M, Watanabe, N et al. (2006). Carcinoembryonic antigen-targeted selective gene therapy for gastric cancer through FZ33 fiber-modified adenovirus vectors. Clin Cancer Res 12: 3803-3813.
27. Baek, H, Uchida, H, Jun, K, Kim, JH, Kuroki, M, Cohen, JB et al. (2011). Bispecific adapter-mediated retargeting of a receptor-restricted HSV-1 vector to CEA-bearing tumor cells. Mol Ther 19: 507-514.
28. Asano, R, Sone, Y, Makabe, K, Tsumoto, K, Hayashi, H, Katayose, Y et al. (2006). Humanization of the bispecific epidermal growth factor receptor x CD3 diabody and its efficacy as a potential clinical reagent. Clin Cancer Res 12: 4036-4042.
29. Gan, HK, Kaye, AH and Luwor, RB (2009). The EGFRvIII variant in glioblastoma multiforme. J Clin Neurosci 16: 748-754.
30. Verhaak, RG, Hoadley, KA, Purdom, E, Wang, V, Qi, Y, Wilkerson, MD et al. (2010). Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17: 98-110.
31. Nakamura, T, Peng, KW, Harvey, M, Greiner, S, Lorimer, IA, James, CD et al. (2005). Rescue and propagation of fully retargeted oncolytic measles viruses. Nat Biotechnol 23: 209-214.
32. Zhou, G and Roizman, B (2007). Separation of receptor-binding and profusogenic domains of glycoprotein D of herpes simplex virus 1 into distinct interacting proteins. Proc Natl Acad Sci USA 104: 4142-4146.
33. Gambini, E, Reisoli, E, Appolloni, I, Gatta, V, Campadelli-Fiume, G, Menotti, L et al. (2012). Replication-competent herpes simplex virus retargeted to HER2 as therapy for high-grade glioma. Mol Ther 20: 994-1001.
34. Estrada, C, Villalobo, A (2006). The Cell Cycle in the Central Nervous System, Janigro, D (ed.). Humana Press: Totowa, NJ, pp. 265-280.
35. Liu, G, Ying, H, Zeng, G, Wheeler, CJ, Black, KL and Yu, JS (2004). HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells. Cancer Res 64: 4980-4986.
36. Menotti, L, Cerretani, A and Campadelli-Fiume, G (2006). A herpes simplex virus recombinant that exhibits a single-chain antibody to HER2/neu enters cells through the mammary tumor receptor, independently of the gD receptors. J Virol 80: 5531-5539.
37. Lavon, I, Zrihan, D, Granit, A, Einstein, O, Fainstein, N, Cohen, MA et al. (2010). Gliomas display a microRNA expression profile reminiscent of neural precursor cells. Neuro-oncology 12: 422-433.
38. Nicola, AV, McEvoy, AM and Straus, SE (2003). Roles for endocytosis and low pH in herpes simplex virus entry into HeLa and Chinese hamster ovary cells. J Virol 77: 5324-5332.
39. Gianni, T, Campadelli-Fiume, G and Menotti, L (2004). Entry of herpes simplex virus mediated by chimeric forms of nectin1 retargeted to endosomes or to lipid rafts occurs through acidic endosomes. J Virol 78: 12268-12276.
40. Frampton, AR Jr, Stolz, DB, Uchida, H, Goins, WF, Cohen, JB and Glorioso, JC (2007). Equine herpesvirus 1 enters cells by two different pathways, and infection requires the activation of the cellular kinase ROCK1. J Virol 81: 10879-10889.
41. Uchida, H, Shah, WA, Ozuer, A, Frampton, AR Jr, Goins, WF, Grandi, P et al. (2009). Generation of herpesvirus entry mediator (HVEM)-restricted herpes simplex virus type 1 mutant viruses: resistance of HVEM-expressing cells and identification of mutations that rescue nectin-1 recognition. J Virol 83: 2951-2961.
42. Nakano, K, Kobayashi, M, Nakamura, K, Nakanishi, T, Asano, R, Kumagai, I et al. (2011). Mechanism of HSV infection through soluble adapter-mediated virus bridging to the EGF receptor. Virology 413: 12-18.
43. Ligas, MW and Johnson, DC (1988). A herpes simplex virus mutant in which glycoprotein D sequences are replaced by beta-galactosidase sequences binds to but is unable to penetrate into cells. J Virol 62: 1486-1494.
44. Otsuki, A, Patel, A, Kasai, K, Suzuki, M, Kurozumi, K, Chiocca, EA et al. (2008). Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses. Mol Ther 16: 1546-1555.
45. Pandita, A, Aldape, KD, Zadeh, G, Guha, A and James, CD (2004). Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR. Genes Chromosomes Cancer 39: 29-36.
46. Liao, S, Khare, PD, Arakawa, F, Kuroki, M, Hirose, Y, Fujimura, S et al. (2001). Targeting of LAK activity to CEA-expressing tumor cells with an anti-CEA scFv/IL-2 fusion protein. Anticancer Res 21(3B): 1673-1680.
47. Highlander, SL, Dorney, DJ, Gage, PJ, Holland, TC, Cai, W, Person, S et al. (1989). Identification of mar mutations in herpes simplex virus type 1 glycoprotein B which alter antigenic structure and function in virus penetration. J Virol 63: 730-738.
48. Mosmann, T (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63.
49. Tomayko, MM and Reynolds, CP (1989). Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 24: 148-154.